Mepsevii® (vestronidase alfa-vjbk)

Mepsevii (vestronidase alfa‑vjbk) is covered only for the FDA‑approved indication of MPS VII (Sly syndrome) — not for other uses — with authorizations for up to 12 months and recommended dosing 4 mg/kg IV every two weeks. Coverage requires confirmed diagnosis by either deficient beta‑glucuronidase enzyme activity (leukocytes, fibroblasts, or serum) or biallelic pathogenic/likely pathogenic GUSB variants, and the drug must be prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder subspecialist, or lysosomal storage disorder specialist.

"Treatment of individuals with mucopolysaccharidosis type VII (MPS VII; Sly syndrome) (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.